contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


flerie-ab-publ-interim-report-january-june-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Flerie

The period in briefNet asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was...

<div class="mfn-body"><p><strong>The period in brief</strong></p><ul><li>Net asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was 4.4 per cent (-0.3).</li><li>Total fair value of shares in portfolio companies was SEK 3,094 million (3,058). Change in fair value of shares in portfolio companies in the quarter was SEK 176 million (172), equivalent to 6.1 per cent (6.2).</li><li>Net profit/loss amounted to SEK 174 million (103).</li><li>Earnings per share before and after dilution amounted to SEK 2.22 (1.59).</li></ul><p><strong>Significant events during the second quarte</strong>r</p><ul><li>The general meetings of Flerie and Toleranzia approved the merger plan announced in the first quarter. The merger is expected to be completed in August.</li><li>Flerie increased its holding in Nanologica, thereby triggering a mandatory bid. A mandatory bid was submitted to the shareholders of Nanologica of SEK 1 per share.</li><li>Flerie divested part of its shareholding in the portfolio company Toleranzia for a total consideration of SEK 15 million.</li><li>The Portfolio company Provell Pharmaceuticals filed for bankruptcy in the U. S. under a Chapter 7-proceeding</li><li>NorthX Biologics secured a significant investment by Signet Healthcare Partners, a leading New York based pharmaservices private equity house.</li></ul><p>Flerie will host a live presentation today, Thursday July 31, at 11:00 CEST. The presentation will be led by Ted Fjällman (CEO) and Cecilia Stureborg von Schéele (CFO), held in English, and followed by a Q&amp;A session.</p><p>If you wish to participate via webcast please register via the link below. Please note that it can take a few minutes to receive the confirmation e-mail with the Teams link following registration.</p><p><strong><a rel="noopener" href="https://events.teams.microsoft.com/event/d7fca2de-0fda-4bf5-9b49-0558f0e16450@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2">https://events.teams.microsoft.com/event/d7fca2de-0fda-4bf5-9b49-0558f0e16450@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2</a></strong></p><p>The presentation will be available after the webcast at <a rel="noopener" href="http://www.flerie.com/">www.flerie.com</a>.</p></div><div class="mfn-footer mfn-contacts mfn-29e5a9386325"><p><strong>For more information:</strong><br>Ted Fjällman, CEO<br>Email: <a rel="noopener" href="mailto:ir@flerie.com">ir@flerie.com</a></p></div><div class="mfn-footer mfn-about mfn-5793c5c817d4"><p><strong class="mfn-heading-1">Flerie in brief</strong><br>Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth&nbsp;opportunities&nbsp;globally alongside other leading investors, focusing predominantly on private&nbsp;companies&nbsp;that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar-vpml"><p><em>This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-31 08:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a579ca7f-ac92-4de7-a34e-18fca3ae3cf9/flerie-interim-report-january-june.pdf" class="mfn-primary">Flerie Interim Report January - June</a></p></div>